authors.affiliation: 1 Klinik für Neurologie, Kantonsspital St. Gallen.|2 Klinik für Hämatologie und Onkologie, Kantonsspital St. Gallen.
authors.forename: Thomas
authors.initials: T
authors.lastname: Hundsberger
authors.affiliation: 3 Klinik für Neurologie, Universitätsspital Zürich.
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality; D059186:Chemoradiotherapy, Adjuvant; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000068258:Bevacizumab
keywords: Bevacizumab; Glioblastom; Glioblastoma; Glioblastome; bevacizumab; facteur de croissance endothélial vasculaire; vascular endothelial growth factor; vaskulärer endothelialer Wachstumsfaktor